The Fifth Circuit's affirmation of Act 358 is a loss for AZN, but the financial impact is likely modest and already anticipated given similar state laws. Monitor for further state legislation and any potential Supreme Court petition. The ruling does not materially change AZN's near-term outlook given its diversified portfolio and $589B market cap.
Price Chart
Executive Summary
The Fifth Circuit affirmed Louisiana's Act 358, which prohibits drug manufacturers from restricting 340B discounted drug delivery to contract pharmacies. AstraZeneca lost its challenge on preemption and Contracts Clause grounds. The ruling is a modest regulatory setback, potentially increasing the volume of 340B discounted sales, but the financial impact is unquantified and likely small relative to AZN's $589B market cap.
Court Ruling Details
Key Facts
- Fifth Circuit affirmed summary judgment for Louisiana, rejecting AstraZeneca's preemption and Contracts Clause challenges to Act 358
- Act 358 bars manufacturers from interfering with 340B drug delivery to contract pharmacies
- Ruling aligns with prior Fifth Circuit precedent in AbbVie v. Fitch regarding Mississippi's similar law
- No damages awarded; no financial impact quantified in the ruling
Financial Impact
Unquantified regulatory setback — potential increase in 340B discounted drug volumes through contract pharmacies, but no immediate financial impact stated
Risk Factors
- Further state laws restricting 340B contract pharmacy restrictions
- Potential increased volume of 340B discounted sales reducing revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-5d791a3776-AZN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $156.97 (−3.02%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $156.97 (+4.16%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $156.97 (−1.92%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.97 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.97 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.97 (−3.39%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.97 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.97 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.97 (−3.39%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $156.97 (+3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access